文献速递糖尿病

2型糖尿病患者使用二甲双胍的贫血风险:MASTERMIND研究

Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study.
PubMed 文献 · Diabetes Care · 2020-08-14

在ADOPT和UKPDS两项随机对照试验及GoDARTS真实世界人群中评估二甲双胍使用与贫血风险的关联及时间进程。结果显示二甲双胍与早期贫血风险升高相关,该发现在两项随机对照试验中一致并在真实世界研究中得到重复。血红蛋白早期下降的机制尚不明确,但根据时间进程,不太可能仅由维生素B12缺乏所致。

要点

  • ADOPT中,与磺脲类相比,二甲双胍贫血OR为1.93(95%CI 1.10, 3.38),噻唑烷二酮类OR为4.18(95%CI 2.50, 7.00)。
  • UKPDS中,与饮食相比,二甲双胍贫血OR为3.40(95%CI 1.98, 5.83),磺脲类OR为0.96(95%CI 0.57, 1.62),胰岛素OR为1.08(95%CI 0.62, 1.87)。
  • GoDARTS中,二甲双胍每1 g/日与年贫血风险升高2%相关。

核心结论

  • 二甲双胍使用与2型糖尿病患者早期贫血风险相关,该发现在两项随机对照试验中一致并在一项真实世界研究中得到重复。
  • 血红蛋白早期下降的机制尚不明确,但根据时间进程,不太可能仅由维生素B12缺乏所致。

研究设计与样本

  • 随机对照试验ADOPT(n=3,967)和UKPDS(n=1,473),采用logistic回归建模贫血风险,非线性混合模型分析血液学参数变化。
  • 观察性GoDARTS人群(n=3,485),采用离散时间失效分析建模累积二甲双胍暴露对贫血风险的影响。
  • 贫血定义为血红蛋白测量值<11 g/dL。

主要发现

  • ADOPT中,与磺脲类相比,二甲双胍贫血OR为1.93(95%CI 1.10, 3.38),噻唑烷二酮类OR为4.18(95%CI 2.50, 7.00)。
  • UKPDS中,与饮食相比,二甲双胍贫血OR为3.40(95%CI 1.98, 5.83),磺脲类OR为0.96(95%CI 0.57, 1.62),胰岛素OR为1.08(95%CI 0.62, 1.87)。
  • ADOPT中,二甲双胍起始后6个月内血红蛋白和血细胞比容下降,3年后无进一步下降。
  • UKPDS中,与其它治疗相比,二甲双胍组血红蛋白在3年时下降;第6年和第9年时所有治疗组血红蛋白均降低,二甲双胍组未见更大差异。
  • GoDARTS中,二甲双胍每1 g/日与年贫血风险升高2%相关。

关键数值与推荐

  • 贫血定义:血红蛋白测量值<11 g/dL。
  • ADOPT中与磺脲类相比贫血OR:二甲双胍1.93(95%CI 1.10, 3.38),噻唑烷二酮类4.18(95%CI 2.50, 7.00)。
  • UKPDS中与饮食相比贫血OR:二甲双胍3.40(95%CI 1.98, 5.83),磺脲类0.96(95%CI 0.57, 1.62),胰岛素1.08(95%CI 0.62, 1.87)。
  • GoDARTS中二甲双胍每1 g/日与年贫血风险升高2%相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 血红蛋白早期下降的机制尚不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the association between metformin use and anemia risk in type 2 diabetes, and the time-course for this, in a randomized controlled trial (RCT) and real-world population data. RESEARCH DESIGN AND METHODS: Anemia was defined as a hemoglobin measure of <11 g/dL. In the RCTs A Diabetes Outcome Progression Trial (ADOPT; n = 3,967) and UK Prospective Diabetes Study (UKPDS; n = 1,473), logistic regression was used to model anemia risk and nonlinear mixed models for change in hematological parameters. In the observational Genetics of Diabetes Audit and Research in Tayside Scotland (GoDARTS) population (n = 3,485), discrete-time failure analysis was used to model the effect of cumulative metformin exposure on anemia risk. RESULTS: In ADOPT, compared with sulfonylureas, the odds ratio (OR) (95% CI) for anemia was 1.93 (1.10, 3.38) for metformin and 4.18 (2.50, 7.00) for thiazolidinediones. In UKPDS, compared with diet, the OR (95% CI) was 3.40 (1.98, 5.83) for metformin, 0.96 (0.57, 1.62) for sulfonylureas, and 1.08 (0.62, 1.87) for insulin. In ADOPT, hemoglobin and hematocrit dropped after metformin initiation by 6 months, with no further decrease after 3 years. In UKPDS, hemoglobin fell by 3 years in the metformin group compared with other treatments. At years 6 and 9, hemoglobin was reduced in all treatment groups, with no greater difference seen in the metformin group. In GoDARTS, each 1 g/day of metformin use was associated with a 2% higher annual risk of anemia. CONCLUSIONS: Metformin use is associated with early risk of anemia in individuals with type 2 diabetes, a finding consistent across two RCTs and replicated in one real-world study. The mechanism for this early fall in hemoglobin is uncertain, but given the time course, is unlikely to be due to vitamin B12 deficiency alone.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Donnelly LA, Dennis JM, Coleman RL, et al. Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study. Diabetes Care. 2020. PMID: 32801130. doi:10.2337/dc20-1104

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。